[en] The aim of the study was to assess in vitro the biocompatibility and the genotoxicity of a gentamicin-loaded monoolein gel intended to treat of chronic osteomyelitis. Indeed, we are developing biodegradable implants based on monoolein and gentamicin. The results of formulations, physico-chemical characterization of the formulated implants and in vitro release kinetic of gentamicin from implants were encouraging. As biocompatibility and absence of genotoxicity are the prerequisites for safe use of implants, we performed in vitro hemolysis, cytotoxicity and, genotoxicity tests. Hemolysis was evaluated by incubating human erythrocytes in direct contact with the implant whereas cytotoxicity was evaluated by 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assay using fibroblasts and macrophages. Alkaline comet Assay was used to evaluate genotoxic potential of the implants. From these in vitro assays, the implant based on monoolein and gentamicin showed no genotoxic potential and has satisfactory biocompatibility.